Last reviewed · How we verify

NCT05860153

Intermittent Levetricetam in Treatment of Febrile Convulsions

Status unknown NA Last updated 16 May 2023
What this trial tests

NA trial testing Levetiracetam in Febrile Convulsion in 100 participants. Status unknown.

Timeline
1 June 2023
Primary endpoint
1 January 2024
1 August 2024

Quick facts

Lead sponsorAssiut University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposescreening
Enrollment100
Start date1 June 2023
Primary completion1 January 2024
Estimated completion1 August 2024

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Adults 6 Months to 36 Months, any sex, with Febrile Convulsion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The American Academy of Pediatrics (AAP) in 2011 published a clinical practice guideline defining a febrile seizure as "a seizure accompanied by fever (temperature ≥ 100.4°F or 38°C by any method), without central nervous system infection, that occurs in infants and children 6 through 60 months of age." Febrile seizures are further classified as simple (generalized in onset, last less than 15 minutes, and do not occur more than once in 24 hours.) or complex (FS duration longer than 15 min, repeated convulsions within the same day, and focal seizure activity or focal findings during the postictal period.).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Levetiracetam

Trials testing the same drug.

Other recruiting trials for Febrile Convulsion

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05860153.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing